Remove FDA Remove Pharma Remove Pharmacology Remove Prescription
article thumbnail

Pharmaceutical Sales Training: Mastering the Art of Modern Pharma Sales

Contrarian Sales Techniques

It's the secret sauce to thriving in the pharma industry. From cutting-edge training techniques that break the mold, to the latest industry trends making waves, and the career development hacks every pharma rep should know – we've got it all covered. Welcome to the world where sales training isn't just a formality.

article thumbnail

How NLP Helps Life Sciences Companies Unlock Insights from Drug Labels

PM360

Typically, a drug label refers to any information provided with prescription drugs, as requested by regulators such as the U.S. Food and Drug Administration (FDA) or European Medicines Agency (EMA). International sources: The focus for many labeling teams is on major sources such as FDA and EMA.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Tapping into digital therapeutics to improve neurological outcomes

Pharmaceutical Technology

Companies are testing the use of digital platforms along with pharmacological treatments. But while appealing, the prospects of developing a merged approach that combines both digital and pharmacological therapeutics remain challenging. Securing reimbursement for digital therapeutics also continues to impede its uptake.

article thumbnail

Why aren’t digital pills taking off?

Pharmaceutical Technology

In 2017, the US Food and Drug Administration (FDA) broke ground by approving the first drug with an embedded biosensor to track its use. Yet, despite the landmark FDA approval, digital pills have not exploded in pharma. But the pharmacology to quantify adherence also depends on race, gender, weight, and other factors.

article thumbnail

Female sexual interest drug reaches tipping point with Phase III plans

Pharmaceutical Technology

After more than a decade in development, Freya Pharma Solutions plans to advance an oral tablet dubbed Lybrido into Phase III trials to treat female sexual interest/arousal disorder (FSIAD). The company plans to submit a request for advice from the FDA at the end of this year or the start of 2023, he adds.

article thumbnail

Legal challenges put off label use of gender affirming care drugs in jeopardy

Pharmaceutical Technology

The laws proposed in several bills range in their potential influence; from restricting the prescription of gender-affirming drugs to criminalising the use of such drugs to allowing states to pursue lawsuits against parents who allow children to access such treatments.

Ethics 144